Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT

Total Page:16

File Type:pdf, Size:1020Kb

Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT Braz J Psychiatry. 2019 xxx-xxx;00(00):000-000 doi:10.1590/1516-4446-2019-0620 Brazilian Psychiatric Association 00000000-0002-7316-1185 ORIGINAL ARTICLE Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial Andre R. Brunoni0000-0000-0000-0000 ,1,2 Angel Carracedo,3 Olalla M. Amigo,3 Ana L. Pellicer,3 Leda Talib,2 Andre F. Carvalho0000-0000-0000-0000 ,4 Paulo A. Lotufo,1 Isabela M. Bensen˜ or,1 Wagner Gattaz,2 Carolina Cappi5 1Departamento de Medicina Interna, Faculdade de Medicina, Universidade de Sa˜o Paulo (USP), Sa˜o Paulo, SP, Brazil. 2Laborato´rio de Neurocieˆncias (LIM-27) and Instituto Nacional de Biomarcadores em Psiquiatria (INBION), Departamento e Instituto de Psiquiatria, Faculdade de Medicina, USP, Sa˜o Paulo, SP, Brazil. 3Grupo de Medicina Xeno´mica/Pharmacogenetics Research, Laboratorio SSL1, Centro Singular de Investigacio´n en Medicina Molecular y Enfermedades Cro´nicas (CiMUS), Santiago de Compostela, Spain. 4Department of Psychiatry, Faculty of Medicine, University of Toronto & Centre for Addiction & Mental Health (CAMH), Toronto, Canada. 5Programa Transtornos do Espectro Obsessivo-Compulsivo, Departamento e Instituto de Psiquiatria, Faculdade de Medicina, USP, Sa˜o Paulo, SP, Brazil. Objective: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression. Methods: Data from the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS) were used. Participants were antidepressant-free at baseline and presented with an acute, moderate-to-severe unipolar depressive episode. They were randomized to receive escitalopram/tDCS-sham (n=75), tDCS/placebo-pill (n=75), or placebo-pill/sham-tDCS (n=45). General linear models assessed the interaction between treatment group and allele-wise carriers. Additional analyses were performed for each group and each genotype separately. Results: Pairwise group comparisons (tDCS vs. placebo, tDCS vs. escitalopram, and escitalopram vs. placebo) did not identify alleles associated with depression improvement. In addition, exploratory analyses also did not identify any SNP unequivocally associated with improvement of depression in any treatment group. Conclusion: Larger, combined datasets are necessary to identify candidate genes for tDCS response. Keywords: Major depressive disorder; non-invasive brain stimulation; single-nucleotide polymorphism; selective serotonin reuptake inhibitors; randomized clinical trial Introduction speculated that, by stimulating the DLPFC, tDCS would increase the activity of the frontoparietal network, con- Transcranial direct current stimulation (tDCS) is a non- sequently leading to an improvement of depressive invasive brain stimulation intervention that consists of the symptoms.5 application of low-intensity electric currents over the scalp Clinically, tDCS excels in safety and tolerability6,7 and to modify brain activity and excitability according to the canevenbeusedathome.8 Nonetheless, tDCS has parameters selected for stimulation.1-3 For major depres- produced mixed outcomes in terms of antidepressant sive disorder (MDD), tDCS is applied over the dorsolateral efficacy.9-12 This may reflect a heterogeneous likelihood prefrontal cortex (DLPFC), a key hub of the frontopa- of response across participants. Therefore, identifying rietal network, which regulates several cognitive functions predictors of response may provide useful insights into and is hypoactive in depression.4 Although the exact anti- tDCS, such as clarifying its mechanisms of action, predic- depressant mechanisms of tDCS remain unclear, it is ting treatment outcomes, and designing better-tailored Correspondence: Andre´ R.Brunoni, Instituto de Psiquiatria, Servic¸o How to cite this article: Brunoni AR, Carracedo A, Amigo OM, Interdisciplinar de Neuromodulac¸a˜o, Rua Dr. Ovı´dio Pires de Campos, Pellicer AL, Talib L, Carvalho AF, et al. Association of BDNF, 785, 2o andar, Ala Sul, CEP 05403-000, Sa˜o Paulo, SP, Brazil. HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and E-mail: [email protected] escitalopram efficacy: ancillary analysis of a double-blind, placebo- Submitted Jul 22 2019, accepted Aug 20 2019 controlled trial. Braz J Psychiatry. 2019;00:000-000. http://dx.doi.org/ . 10.1590/1516-4446-2019-0620 2 AR Brunoni et al trials within the framework of precision psychiatry.2,13,14 In Methods this context, the investigation of genomic variants, such as common single nucleotide polymorphisms (SNPs), Trial design has been considered a promising avenue to tailor anti- depressant strategies.15-17 Furthermore, compared to This is an ancillary study of the Escitalopram versus Electrical Current Therapy for Treating Depression other biological markers such as magnetic resonance imaging (MRI) and electroencephalography (EEG), Clinical Study (ELECT-TDCS), a non-inferiority, placebo- controlled trial in which the efficacy of tDCS, escitalopram, SNPs are relatively more available and affordable to 19,31 18 and placebo were evaluated. The ELECT-TDCS collect and analyse. 19,31 In the present study, we investigated whether specific trial (clinicaltrials.gov number NCT01894815) took SNPs involved in MDD pathophysiology were associated place from 2013 to 2016 at the Universidade de 19 Sa˜o Paulo, the capital of the state of Sa˜o Paulo, Brazil. with tDCS response. According to our study protocol, Participants were randomized to receive escitalopram- the following genes and SNPs associated with treatment response in MDD, neuroplasticity, and serotonin metabo- pill/sham-tDCS (henceforth, escitalopram), placebo-pill/ active-tDCS (tDCS), or placebo-pill/sham-tDCS (placebo) lism were investigated: in a 3:3:2 ratio. ELECT-TDCS was designed to demonstrate noninfer- a) brain-derived neurotrophic factor (BDNF, rs6265, chro- iority of escitalopram vs. tDCS. Specifically, noninferiority mosome 11p13): the BDNF gene was chosen because would be proven if the improvement in the tDCS vs. placebo the factor it encodes plays a key role in synaptic plasticity, groups was at least 50% of the improvement achieved in the depression and antidepressant response.20 The most escitalopram vs. placebo groups at the primary endpoint frequent BDNF genetic variation is the 196G/A (rs6265) 0 (week 10) on our primary outcome scale, the Hamilton SNP, which causes a change from Val to Met at the 5 -pro Depression Rating Scale, 17 items (HDRS-17). Briefly, the protein site. This polymorphism disrupts cellular traffick- original study showed a mean (standard deviation [SD]) ing, processing, and BDNF secretion,21 and impairs depression improvement in HDRS-17 of 11.3 (6.5) for synaptic transmission and cortical plasticity.22 Although escitalopram, 9 (7.1) for tDCS, and 5.8 (7.9) for placebo. we did not observe an influence of rs6265 on tDCS res- The main findings showed that tDCS was not noninferior ponse in an earlier study,23 our analyses might have been to escitalopram, as the lower boundary of the confidence underpowered. interval for the difference in the decrease of tDCS vs. b) solute carrier family 6 member 4 (SLC6A4, rs25531, escitalopram, a difference of -2.3 (95% confidence inter- chromosome 17q11.1-q12): SLC6A4 codifies the presy- val [95%CI] -4.3 to -0.4), was lower than the noninferiority naptic serotonin reuptake transporter (SERT) and is margin of -2.75. Secondary analyses showed that esci- characterized by a functional 44-bp insertion/deletion talopram and tDCS were both superior to placebo, and polymorphism (5HTTLPR) in its promoter region.24 This confirmed that escitalopram was superior to tDCS. More- SNP was chosen because it has been consistently asso- over, moderator analyses did not identify any clinical ciated with selective serotonin reuptake inhibitor (SSRI) or demographic predictor associated with treatment res- antidepressant response25; ponse for any intervention group. c) tryptophan hydroxylase 1 (TPH1, rs1800532, chromo- In ELECT-TDCS, we additionally investigated several some 11p15.3-p14) polymorphism: the TPH enzyme biological markers that could be associated with clinical metabolizes L-tryptophan to 5-HTP, which is then metab- depression outcomes, such as plasma biomarkers and olized to serotonin by the enzyme 5-HTP decarboxylase. motor cortical excitability.31,32 Here, we report data from TPH regulates the activity of this metabolic pathway and, the participants who finished the study and had at least therefore, the availability of serotonin. Although the TPH1 one blood sample collected at baseline for genotyping. isoform is less expressed in the brain than TPH2, the TPH1 gene has been particularly associated with anti- depressant effects17; Subjects d) 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012, chromosome 13q14-q21) genes: this Participants with unipolar depression aged 18 to 75 years G protein-coupled receptor triggers long-term, intracellu- were included. Diagnoses were established by certified lar effects when activated and therefore plays a critical psychiatrists using the DSM-5
Recommended publications
  • Serotonin Receptor 2A (HTR2A) Gene Polymorphism Predicts Treatment Response to Venlafaxine XR in Generalized Anxiety Disorder
    The Pharmacogenomics Journal (2013) 13, 21–26 & 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13 www.nature.com/tpj ORIGINAL ARTICLE Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder FW Lohoff1,2, TD Aquino1, Generalized anxiety disorder (GAD) is a chronic psychiatric disorder with 2 2 significant morbidity and mortality. Antidepressant drugs are the preferred S Narasimhan , PK Multani , choice for treatment; however, treatment response is often variable. Several 1 1 B Etemad and K Rickels studies in major depression have implicated a role of the serotonin receptor gene (HTR2A) in treatment response to antidepressants. We tested the 1Mood & Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of hypothesis that the genetic polymorphism rs7997012 in the HTR2A gene Medicine, Philadelphia, PA, USA and predicts treatment outcome in GAD patients treated with venlafaxine XR. 2Department of Psychiatry, Psychiatric Treatment response was assessed in 156 patients that participated in a Pharmacogenetics Laboratory, Center for 6-month open-label clinical trial of venlafaxine XR for GAD. Primary analysis Neurobiology and Behavior, University of Pennsylvania School of Medicine, Philadelphia, included Hamilton Anxiety Scale (HAM-A) reduction at 6 months. Secondary PA, USA outcome measure was the Clinical Global Impression of Improvement (CGI-I) score at 6 months. Genotype and allele frequencies were compared between Correspondence: groups using w2 contingency analysis. The frequency of the G-allele differed Dr FW Lohoff, Department of Psychiatry, significantly between responders (70%) and nonresponders (56%) at Translational Research Laboratory, Center for Neurobiology and Behavior, University of 6 months (P ¼ 0.05) using the HAM-A scale as outcome measure.
    [Show full text]
  • Pharmacogenomic Characterization in Bipolar Spectrum Disorders
    pharmaceutics Review Pharmacogenomic Characterization in Bipolar Spectrum Disorders Stefano Fortinguerra 1,2 , Vincenzo Sorrenti 1,2,3 , Pietro Giusti 2, Morena Zusso 2 and Alessandro Buriani 1,2,* 1 Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy; [email protected] (S.F.); [email protected] (V.S.) 2 Department of Pharmaceutical & Pharmacological Sciences, University of Padova, 35131 Padova, Italy; [email protected] (P.G.); [email protected] (M.Z.) 3 Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy * Correspondence: [email protected] Received: 25 November 2019; Accepted: 19 December 2019; Published: 21 December 2019 Abstract: The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice.
    [Show full text]
  • Gene Polymorphisms of Serotonin Receptors and Drug-Induced Hyperprolactinemia in Patients with Schizophrenia
    Poster number: P.3.b.037 Gene polymorphisms of serotonin receptors and drug-induced hyperprolactinemia in patients with schizophrenia Diana Z. Оsmanova1, Anastasia S. Boiko1, Olga Yu. Fedorenko1, Ivan V. Pozhidaev1, M.B. Freidin1 Elena G. Kornetova1, Svetlana A. Ivanova1 , Bob Wilffert2, Anton J.M. Loonen2 1. Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia 2. Department of Pharmacy, University of Groningen, Groningen, The Netherlands BACKGROUND RESULTS Antipsychotic drug-induced hyperprolactinemia is an All patients with schizophrenia were divided into two increasingly prevalent problem in current psychiatric practice and groups: those with and without hyperprolactinemia. Patients responsible for troublesome side effects like loss of libido and from both groups were genotyped for HTR1A variants: rs6295, impotence. The chance to develop hyperprolactinemia depends rs1364043, rs10042486, rs1800042, rs749099; for HTR1B: upon the pharmacological properties of antipsychotic medication rs6298, rs6296, rs130058; for HTR2A: rs6311, rs6313, rs6314, used, of its dosage and treatment duration, as well as from the rs7997012, rs1928040, rs9316233, rs2224721, rs6312; for genetic make-up and other characteristics which determine the HTR2C: rs6318, rs5946189, rs569959, rs17326429, rs4911871, individual sensitivity of the individual patient. rs3813929, rs1801412, rs12858300; for HTR3A: rs1062613, Second generation antipsychotics are (often) more potent rs33940208, rs1176713; for HTR3B:
    [Show full text]
  • Genetic and Epigenetic Influences on Schizotypal Cognition
    Genetic and Epigenetic Influences on Schizotypal Cognition by Emma Leah Leach B.Sc. (Hons., Biology), University of Western Ontario, 2011 Thesis Submitted In Partial Fulfillment of the Requirements for the Degree of Master of Science in the Department of Biological Sciences Faculty of Science Emma Leah Leach 2013 SIMON FRASER UNIVERSITY Summer 2013 Approval Name: Emma Leah Leach Degree: Master of Science (Biology) Title of Thesis: Genetic and Epigenetic Influences on Schizotypal Cognition Examining Committee: Chair: Dr. Gerhard Gries Professor Dr. Bernard Crespi Senior Supervisor Professor Dr. Felix Breden Supervisor Professor, Departmental Chair Dr. Gratien Prefontaine Supervisor Assistant Professor Dr. Julian Christians Internal Examiner Associate Professor Department of Biological Sciences Date Defended/Approved: August 13, 2013 ii Partial Copyright Licence iii Ethics Statement The author, whose name appears on the title page of this work, has obtained, for the research described in this work, either: a. human research ethics approval from the Simon Fraser University Office of Research Ethics, or b. advance approval of the animal care protocol from the University Animal Care Committee of Simon Fraser University; or has conducted the research c. as a co-investigator, collaborator or research assistant in a research project approved in advance, or d. as a member of a course approved in advance for minimal risk human research, by the Office of Research Ethics. A copy of the approval letter has been filed at the Theses Office of the University Library at the time of submission of this thesis or project. The original application for approval and letter of approval are filed with the relevant offices.
    [Show full text]
  • Exploration of 19 Serotoninergic Candidate Genes in Adults and Children with Attention-Deficit/Hyperactivity Disorder Identifies
    Molecular Psychiatry (2009) 14,71–85 & 2009 Nature Publishing Group All rights reserved 1359-4184/09 $32.00 www.nature.com/mp ORIGINAL ARTICLE Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB M Ribase´s1,11, JA Ramos-Quiroga1,2,11, A Herva´s3, R Bosch1, A Bielsa1, X Gastaminza1, J Artigas4, S Rodriguez-Ben3, X Estivill5,6,7, M Casas1,2, B Cormand8,9,10 and M Baye´s5,6,7 1Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Catalonia, Spain; 2Department of Psychiatry and Legal Medicine, Universitat Auto´noma de Barcelona, Barcelona, Catalonia, Spain; 3Child and Adolescent Mental Health Unit, Department of Psychiatry, Hospital Mu´tua de Terrassa, Barcelona, Catalonia, Spain; 4Unitat de Neuropediatria, Hospital de Sabadell, Corporacio´ Sanita`ria Parc Taulı´, Barcelona, Catalonia, Spain; 5Genes and Disease Program, Center for Genomic Regulation (CRG), UPF, Barcelona, Catalonia, Spain; 6Centro Nacional de Genotipado (CeGen), Barcelona, Catalonia, Spain; 7CIBER Epidemiologı´a y Salud Pu´blica, Instituto de Salud Carlos III (CRG), Barcelona, Catalonia, Spain; 8Departament de Gene`tica, Facultat de Biologia, Universitat de Barcelona, Barcelona, Catalonia, Spain; 9CIBER Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Catalonia, Spain and 10Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Catalonia, Spain Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in which different genetic and environmental susceptibility factors are involved. Several lines of evidence support the view that at least 30% of ADHD patients diagnosed in childhood continue to suffer the disorder during adulthood and that genetic risk factors may play an essential role in the persistence of the disorder throughout lifespan.
    [Show full text]
  • Pharmacogenetics of Antidepressants, a Review Of
    al Depres ic sio lin n C Reyes-Barron et al., Clin Depress 2016, 2:2 Clinical Depression Research Article Article OpenOpen Access Access Pharmacogenetics of Antidepressants, A Review of Significant Genetic Variants in Different Populations Cynthia Reyes-Barron1, Silvina Tonarelli1, Andrew Delozier1, David F. Briones1, Brenda B. Su2, Lewis P. Rubin1 and Chun Xu1* 1Texas Tech University Health Sciences Centre, Paul L. Foster School of Medicine 2College of Medicine and Health Sciences, UAE University, Department of Internal Medicine Abstract Major depressive disorder is a highly prevalent disease that is challenging to treat, often requiring medication and dose adjustments. Genetic factors play an important role in psychotropic medication responses. However, the translation of pharmacogenetics findings to clinical recommendations with regards to antidepressant responses is still in its early stages. We reviewed recent primary research articles, meta-analyses, and reviews on the pharmacogenetics of antidepressant treatment for major depressive disorder in different populations. We identified eight genes with likely associations with treatment responses and summarized genetic variants most likely to influence treatment responses. We determined the frequency of these variants in Caucasian, Asian, Hispanic, and African American populations. The genes are related to functions in drug metabolism, transport, signalling, stress response, and neuroplasticity. Clinical recommendations already exist for CYP2D6 and CYP2C19 cytochrome P450 drug metabolism genes. The other genes are: ABCB1 with single nucleotide polymorphisms (SNPs) rs2032583 and rs2235015; FKBP5 with SNPs rs1360780, rs3800373, and rs4713916; GNB3 with SNP rs5443; BDNF with SNP rs6265; HTR2A with SNPs rs7997012 and rs6313; and SLC6A4 with polymorphisms 5-HTTLPR and STin2. There is significant variability of the frequencies of these polymorphisms in the different populations we reviewed.
    [Show full text]
  • A Serotonin Receptor with a Possible Role in Joint Diseases
    Anders Kling 5-HT2 A – a serotonin receptor with a possible role in joint diseases role with a possible receptor – a serotonin 5-HT2A – a serotonin receptor with a possible role in joint diseases Anders Kling Umeå University 2013 Umeå University Department of Pharmacology and Clinical Neuroscience New Serie 1547 Department of Pharmacology and Clinical Neurosciences Umeå University ISSN: 0346-6612 Umeå University, Sweden 2013 SE-901 87 Umeå, Sweden ISBN 978-91-7459-549-9 5-HT2A – a serotonin receptor with a possible role in joint diseases Anders Kling Institutionen för farmakologi och klinisk neurovetenskap, Klinisk farmakologi/ Department of Pharmacology and Clinical Neuroscience, Clinical Pharmacology Umeå universitet/ Umeå University Umeå 2013 Responsible publisher under swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7459-549-9 ISSN: 0346-6612 New series No: 1547 Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print och Media, Umeå universitet Umeå, Sweden 2013 Innehåll/Table of Contents Innehåll/Table of Contents i Abstract iv Abbreviations vi List of studies viii Populärvetenskaplig sammanfattning ix 5-HT2A – en serotoninreceptor med möjlig betydelse för ledsjukdomar ix Introduction 1 The serotonin system 1 Serotonin 1 Serotonin receptors 2 The serotonin system and platelets 2 Serotonin receptor 5-HT2A 3 Localisation/expression of 5-HT2A receptors 3 Functions of the 5-HT2A receptor 4 Regulation of the 5-HT2A receptor
    [Show full text]
  • Molecular Genetics of Human Personality Traits for Psychiatric, Behav- Ioral, and Substance-Related Disorders Eugene Lin*,1 and Po See Chen*,2,3
    The Open Translational Medicine Journal, 2009, 1, 1-8 1 Open Access Molecular Genetics of Human Personality Traits for Psychiatric, Behav- ioral, and Substance-Related Disorders Eugene Lin*,1 and Po See Chen*,2,3 1Vita Genomics, Inc., 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan 2Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan 3National Cheng Kung University Hospital and Dou-Liou Branch, Taiwan Abstract: The investigation of personality genetics had received much attention since the three seminal reports showing an association between genes and personality traits in the general population. Accumulating evidences suggested that per- sonality traits have significant genetic components. Although currently available data are not enough for proof, more and more genetic variants associated with personality traits are being discovered. In this paper, we review related studies of gene polymorphisms and human personality traits for psychiatric, behavioral, and substance-related disorders. First, we briefly describe the commonly-used self-reported temperament measures that define personality dimensions. Then, we summarize the characteristics of the candidate genes for personality traits, and investigate gene variants which have been suggested to be linked with personality traits for individuals with psychiatric, behavioral, and substance-related disorders. Keywords: Molecular genetics, personality, psychiatric disorders, temperament measures. 1. INTRODUCTION and 5-HTTLPR but not other anxiety-related personality traits [14,15]. The investigation of personality genetics had received much attention since the three seminal reports [1-3] in 1996 We reviewed related studies of gene polymorphisms and showing an association between genes and personality traits human personality traits for psychiatric, behavioral, and sub- in the general population.
    [Show full text]
  • Rightmed Comprehensive Test Report
    Making prescriptions personal RightMed® comprehensive test report The RightMed comprehensive test is a pharmacogenomic test that identi]es how a patient’s DNA affects their response to hundreds of medications. This report can be used to help determine safer, more effective medications and doses tailored to a patient’s unique genomic pro]le. Additional reports, including RightMed Advisor custom reports and specialty reports, are available through the provider portal at portal.oneome.com. Patient and report summary Patient name: Jane Doe Ordering provider: Sample Doctor Patient date of birth: 1972-07-08 Ordering facility: Healthcare Institution OneOme report date: 2018-05-17 Product type: Comprehensive Report type: Original Report legend Based on the genes in our panel, medications are reported according to genotype-predicted interactions described below. Major gene-drug Major genotype-drug interaction identi]ed that affects the metabolism of the medication and/or interaction indicates an elevated risk of adverse reaction or loss of e_cacy. Moderate gene-drug Moderate genotype-drug interaction identi]ed that affects the metabolism of the medication and/or interaction indicates an elevated risk of adverse reaction or loss of e_cacy. Minimal gene-drug Minimal genotype-drug interaction identi]ed that does not signi]cantly impact medication interaction metabolism or predict an elevated risk of adverse reaction or loss of e_cacy. Icon legend Some medications are reported with icons to indicate that additional information is available. Consult the RightMed Advisor for more information on speci]c clinical annotations and/or dosing guidelines provided by the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Dutch Pharmacogenomics Working Group (DPWG), the Food and Drug Administration (FDA), and/or other professional guidelines.
    [Show full text]
  • Association Between Single Nucleotide Polymorphisms Of
    Uniwersytet Medyczny w Łodzi Medical University of Lodz https://publicum.umed.lodz.pl Association between single nucleotide polymorphisms of TPH1 and TPH2 genes, and depressive disorders, Publikacja / Publication Wigner Paulina, Czarny Piotr, Synowiec Ewelina, Bijak Michał, Białek Katarzyna, Talarowska Monika, Gałecki Piotr, Szemraj Janusz, Śliwiński Tomasz DOI wersji wydawcy / Published http://dx.doi.org/10.1111/jcmm.13459 version DOI Adres publikacji w Repozytorium URL / Publication address in https://publicum.umed.lodz.pl/info/article/AML5be93f423a3b45c8a7c46dab8af0d433/ Repository Rodzaj licencji / Type of licence Attribution (CC BY) Wigner Paulina, Czarny Piotr, Synowiec Ewelina, Bijak Michał, Białek Katarzyna, Talarowska Monika, Gałecki Piotr, Szemraj Janusz, Śliwiński Tomasz: Association Cytuj tę wersję / Cite this version between single nucleotide polymorphisms of TPH1 and TPH2 genes, and depressive disorders, Journal of Cellular and Molecular Medicine, Blackwell Publishing, vol. 22, no. 3, 2018, pp. 1778-1791, DOI:10.1111/jcmm.13459 J. Cell. Mol. Med. Vol 22, No 3, 2018 pp. 1778-1791 Association between single nucleotide polymorphisms of TPH1 and TPH2 genes, and depressive disorders Paulina Wigner a, Piotr Czarny b, Ewelina Synowiec a, Michał Bijak c, Katarzyna Białek a, Monika Talarowska d, Piotr Galecki d, Janusz Szemraj b, Tomasz Sliwinski a, * a Laboratory of Medical Genetics, Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland b Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland c Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland d Department of Adult Psychiatry, Medical University of Lodz, Lodz, Poland Received: August 23, 2017; Accepted: October 16, 2017 Abstract Tryptophan catabolites pathway disorders are observed in patients with depression.
    [Show full text]
  • Case–Control Association Study of 59 Candidate Genes Reveals the DRD2
    Journal of Human Genetics (2009) 54, 98–107 & 2009 The Japan Society of Human Genetics All rights reserved 1434-5161/09 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population Elitza T Betcheva1, Taisei Mushiroda2, Atsushi Takahashi3, Michiaki Kubo4, Sena K Karachanak5, Irina T Zaharieva5, Radoslava V Vazharova5, Ivanka I Dimova5, Vihra K Milanova6, Todor Tolev7, George Kirov8, Michael J Owen8, Michael C O’Donovan8, Naoyuki Kamatani3, Yusuke Nakamura1,9 and Draga I Toncheva5 The development of molecular psychiatry in the last few decades identified a number of candidate genes that could be associated with schizophrenia. A great number of studies often result with controversial and non-conclusive outputs. However, it was determined that each of the implicated candidates would independently have a minor effect on the susceptibility to that disease. Herein we report results from our replication study for association using 255 Bulgarian patients with schizophrenia and schizoaffective disorder and 556 Bulgarian healthy controls. We have selected from the literatures 202 single nucleotide polymorphisms (SNPs) in 59 candidate genes, which previously were implicated in disease susceptibility, and we have genotyped them. Of the 183 SNPs successfully genotyped, only 1 SNP, rs6277 (C957T) in the DRD2 gene (P¼0.0010, odds ratio¼1.76), was considered to be significantly associated with schizophrenia after the replication study using independent sample sets. Our findings support one of the most widely considered hypotheses for schizophrenia etiology, the dopaminergic hypothesis.
    [Show full text]
  • Flight Behaviour in Humans Is Intensified by a Candidate Genetic Risk Factor for Panic Disorder: Evidence from a Translational Model of Fear and Anxiety
    Molecular Psychiatry (2010), 1–2 & 2010 Nature Publishing Group All rights reserved 1359-4184/10 $32.00 www.nature.com/mp LETTER TO THE EDITOR Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety Molecular Psychiatry advance online publication, 23 iourally, as the intensity of flight effort in response to February 2010; doi:10.1038/mp.2010.2 a pursuing threat stimulus.5 The genetic risk factor for PD used in this study was the C allele of the 102T/C single-nucleotide polymorphism (rs6313) within the Panic disorder (PD) is a serious and common serotonin 2a receptor gene (HTR2A) on chromosome psychiatric condition1 characterized mainly by recur- 13q14.2; the C allele in this SNP is known to be rent episodes of intense, uncontrollable fear known as associated with increased susceptibility to pure but panic attacks.2 The underlying causal mechanism for not co-morbid PD,6 as well as to increased intensity of PD is unknown;3 however, the discovery that drugs panic symptoms.7 All 200 participants (107 of whom with clinical effectiveness against PD preferentially were male) gave informed consent and self-identified alter rodent flight behaviour suggests that PD reflects as healthy Caucasians. Buccal cells were collected alterations in the brain systems that govern flight.4 and DNA extracted using established methods (see An association between PD and flight in humans Supplementary Information). is supported anecdotally by the tendency for PD The genotype distribution of rs6313 SNP in HTR2A sufferers to feel a strong urge to flee from the location was in Hardy–Weinberg equilibrium (w2 = 0.632, where a panic attack occurs.2 Here we provide the d.f.
    [Show full text]